In this study, we aimed to evaluate the exact contribution of miR-21 in the pathogenesis and progression of NASH and to evaluate the therapeutic potential of the simultaneous activation of PPARα as a result of miR-21 ablation, and FXR, by administering OCA. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatohepatitis.